AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01129414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Pharmaceutical form: delayed-release capsule~Route of administration: oral
Study NCT01329900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 150 mg/m2 by vein over 2 hours every 12 hours Days 2, 3, and 4 for 6 doses.
Study NCT01329900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: 2 gm/m2 by vein over 1 hour on Day 2 (given before Ifosfamide starts)~2.66 gm/m2/day by vein continuous infusion given over 24 hours daily for 3 days starting on Day 2 (together with Ifosfamide)~After Ifosfamide/Mesna, 2 gm/m2 by vein given over 12 hours for one dose.
Study NCT01329900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: 6 mcg/kg subcutaneously twice a day on day 6 (rounded off to the nearest vial) until completion of apheresis.
Study NCT01329900 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Collection
Description: Blood stem cells will be collected when blood counts have returned to normal (about 10-16 days after chemotherapy). Stem cell collection takes about 4 hours each time.
Study NCT01025115 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Diamel
Description: Two Diamel tablets (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 12 months, together with the standard treatment for metabolic syndrome consisting in appropriate diet according to patient's weight and physical activity, and appropriate hypertensive drugs (generally ACE inhibitors) for hypertension. Patient´s were also verbally encouraged to increase physical activity (to walk for 30-45 minutes a day 3-4 days a week).
Study NCT01025115 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two Placebo tablets (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 12 months, together with the standard treatment for metabolic syndrome consisting in appropriate diet according to patient's weight and physical activity, and appropriate hypertensive drugs (generally ACE inhibitors) for hypertension. Patient´s were also verbally encouraged to increase physical activity (to walk for 30-45 minutes a day 3-4 days a week).
Study NCT01606436 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.
Study NCT01606436 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Moxifloxacin
Description: Administered orally.
Study NCT02742610 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness with Contingency Management
Study NCT02742610 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Study NCT02658929 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bb2121
Description: bb2121
Study NCT05123261 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: the mindfulness-based elder care (MBEC) therapy
Description: According to the mindfulness-based elder care (MBEC) therapy developed by McBee (2008), the experimental group was offered eight 50-minute courses once a week.
Study NCT02984748 — intervention group
Intervention type: DEVICE
Intervention: Cochlear implant
Study NCT02003820 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: video modeled social story
Description: Patient will watch a Youtube compatible video of a child in the same age range as the study participants demonstrating proper brushing technique. The video will be paired with written subtitles created using the Social Story format. The subtitles will be read to the participant as the video plays. The patient will watch the video immediately before each brushing session morning and night for the three week intervention. After the intervention period the video will be made available on Youtube.com for the participants to use as they wish.
Study NCT06075524 — intervention group
Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo blood and optional stool/tissue sample collection
Study NCT06075524 — intervention group
Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Medical records are reviewed
Study NCT04540679 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: VIP4SCI
Description: Technology-enabled self-management \& rehabilitation solution
Study NCT00972049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2516
Description: Capsule administered once orally. Specific dose depends on dose panel.
Study NCT00972049 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule administered once orally
Study NCT01300975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pentavalent antimony
Description: 3 intralesional injections of antimony at D1, D3 and D7
Study NCT01300975 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cryotherapy
Description: Frozing of lesions with liquid nitrogen ad D1 and D14
Study NCT03837002 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: foot care protocol
Description: foot assesment, foot care, foot care education
Study NCT02845193 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modified Nasoalveolar molding
Description: Infants will receive this appliance which is a maxillary plate with nasal stent in addition to taping on the upper lip (taping is routine step in Grayson's nasoalveolar molding technique).
Study NCT01300975 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo cream
Description: topical emollient crean 3 times a day during 21 days
Study NCT00426829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10 mg/kg by vein every 14 days +/- 2 days, starting on day 1.
Study NCT00426829 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Radiation Therapy
Description: 3 Gy dose/fraction x 20 fractions.
Study NCT02348632 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: JZP-110
Study NCT02845193 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Taping
Description: Infants will receive a tape only on the upper lip segments to mold it to touch each other.
Study NCT04041544 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SN1011
Description: SN1011 will be supplied to the Pharmacy as 25 mg and 100 mg capsules.
Study NCT04041544 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SN1011 placebo
Description: The placebo to be used in this study will be identical to SN1011, minus the active ingredient.
Study NCT03148600 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor and bowel behavioural training
Description: Physiotherapist-led pelvic floor muscle and bowel behavioural training
Study NCT03148600 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard arm
Description: Standard medical and nursing care
Study NCT01158417 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study NCT01158417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resveratrol 40 mg oral three times a day
Description: Drug
Study NCT01158417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resveratrol 500 mg oral once daily.
Description: Resveratrol 500 mg oral once daily.
Study NCT01129414 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Omeprazole
Description: Pharmaceutical form: delayed-release capsule~Route of administration: oral
Study NCT00949104 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sucrose
Description: 1 ml of 24% sucrose was administered 2 minutes prior to the procedure
Study NCT00949104 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Double distilled water
Description: 1 ml of double distilled water (Placebo) was administered 2 minutes prior to the procedure
Study NCT04552067 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lovenox
Description: patients given curative dose of Lovenox
Study NCT04552067 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: patients given curative dose of Enoxa
Study NCT04330989 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iNSC and Adherence supporter training
Description: Integrated next step counseling: iNSC is a structured, patient-centered approach informed by motivational interviewing techniques, which aims to foster an environment for joint-problem solving in order that the participant may identify their individual needs to increase or sustain sexual health through biomedical and non-biomedical approaches. iNSC frames the counselling sessions as a non-judgmental discussion to explore the facilitators and challenges to sexual health and medication adherence.~Adherence supporter training: Participants will be asked to identify a partner, family member, or friend to whom they are willing to disclose their HIV status (for HIV-positive women) or their intent to initiate PrEP (for HIV-negative women). Participants may also select a clinic-based peer to serve this adherence supporter role. Trainings will emphasize basic HIV knowledge, importance of antiretroviral adherence, potential drug side effects, and practical strategies for supporting adherence.
Study NCT01803529 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: heat-pack with massage
Study NCT01803529 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: heat-pack only
Study NCT03824457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rheosorbilact®
Description: Rheosorbilact® is administered as a part of the infusion therapy intravenously (with speed 40-60 drip per minute) at a dose of not more than 400 ml (6 to 7 ml/kg body weight per 24 hours) for 3 days.
Study NCT03824457 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer lactate
Description: Rheosorbilact® is administered as a part of the infusion therapy intravenously (with speed 40-60 drip per minute) at a dose of not more than 400 ml (6 to 7 ml/kg body weight per 24 hours) for 3 days.
Study NCT04347252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon
Description: Intravenous infusion of glucagon at fasting or elevated glycemia. Blockade of the GLP-1 receptor during hyperglycemia with and without glucagon.
Study NCT00298311 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mci guidance peer support
Description: 12 weeks of home visits by peer mentor recovered from PPD and Keys to Caregiving (NCAST, 1990) program
Study NCT00298311 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: mci guidance peer support
Description: 12 weeks of home visits by peer mentor recovered from PPD and Keys to Caregiving (NCAST, 1990) program
Study NCT02159989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapanisertib
Description: Given PO
Study NCT02159989 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ziv-Aflibercept
Description: Given IV
Study NCT03196973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DF289 plus DF277
Description: 1 vial into the affected ear twice daily for 7 days
Study NCT03196973 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DF289
Description: 1 vial into the affected ear twice daily for 7 days
Study NCT03196973 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DF277
Description: 1 vial into the affected ear twice daily for 7 days
Study NCT03675594 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CAD/CAM titanium denture base
Description: metallic denture base made of titanium
Study NCT03675594 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CAD/CAM cobalt/chromium denture bases
Description: metallic denture bases made of cobalt/chromium
Study NCT02490904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone
Description: Double-blinded Eplerenone administered for 4 days at 25mg every 12 hours
Study NCT02490904 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Double-blinded Placebo administered for 4 days at 25mg every 12 hours
Study NCT04124406 — intervention group
Intervention type: DEVICE
Intervention: Cologuard
Description: multi-target stool Deoxyribonucleic Acid (MT-sDNA) screening test
Study NCT00673816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib Malate
Description: Participants were expected to receive 9 months of sunitinib malate therapy administered in 6 cycles. Each cycle consisted of a daily oral dose of 50 mg sunitinib malate for 4 weeks followed by a 2-week rest period).
Study NCT01222416 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiopharmaceutical Administration [18F]-FDG
Description: Adult dose: (0.15 mCi/kg ranging from 3 to 16 mCi,route IV. Time interval between administration and scanning: 60 +/- 10minutes post-injection.
Study NCT01222416 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiopharmaceutical: [18F]-FLT
Description: Adult dose: (0.15 mCi/kg ranging from 3 to 16 mCi), route = IV, Time interval between administration and scanning: 60 +/- 10minutes post-injection.
Study NCT03114462 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Hypofractionated Radioablation
Description: Starting dose is 8.0 Gy per fraction for 5 fractions (total dose = 40.0 Gy). Subsequent cohorts of participants receive an additional 0.5 Gy per fraction.
Study NCT03114462 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Quality of life and symptom questionnaires completed at: Baseline, on days receiving HYDRA, 6 weeks after last dose of HYDRA, 3 months after last dose of HYDRA, and 6 months after last dose of HYDRA. Also after the 6 month follow-up visit, every 3 months for the first 2 years, and then every 6 months after that for up to 5 years.
Study NCT00584987 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone furoate
Description: 2 puffs of each nasal spray in each nostril in the pm
Study NCT00584987 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Fluticasone furoate
Description: 2 puffs of each nasal spray in each nostril in the pm
Study NCT00584987 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Fluticasone furoate
Description: 2 puffs of each nasal spray in each nostril in the pm
Study NCT00584987 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxymetazoline
Description: 2 puffs of each nasal spray in each nostril in the pm
Study NCT00584987 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Oxymetazoline
Description: 2 puffs of each nasal spray in each nostril in the pm
Study NCT00584987 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oxymetazoline
Description: 2 puffs of each nasal spray in each nostril in the pm
Study NCT00881023 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microfracture
Description: The microfracture procedure is a standard method for treatment of cartilage damage in which the surgeon will clean the site of your cartilage damage and then will make several small holes in your bone to stimulate your bone marrow with the intention to repair the damaged area with new cartilage tissue
Study NCT00881023 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cartilage Autograft Implantation System
Description: A surgical treatment of damaged knee cartilage using the subject's own healthy cartilage obtained from a non-weight or low weight-bearing region
Study NCT03727776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adrenocorticotropic Hormone
Description: Adrenocorticotropic hormone (ACTH) is a melanocortin peptide hormone that is normally produced in the pituitary gland and acts as a major regulator of adrenal cortex function. It stimulates the adrenal cortex to produce and secrete glucocorticoids. ACTH is available for clinical usage as an injectable gel (H.P. Acthar®).
Study NCT03780088 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mTranS-C
Description: mobile health
Study NCT02906098 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient centered oral health education
Description: Procedure: The theory-based educational intervention follows a specific structure. The initial phase contain 3 treatment sessions (45-60 min each) during a period of 12 weeks (baseline, 2-3 weeks and 10-12 weeks). Follow up are performed at 6- and 18-months.
Study NCT02906098 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard educational intervention
Description: Procedure: The initial phase contain educational intervention in accordance with conventional routines (oral health information and oral hygiene instruction at one or several occasions). Follow up are performed at 6- and 18-months.
Study NCT03567590 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulsed Radiofrequency treatment
Description: The pulse treatment generator (PMF-21-100-5, Baylis Medical Inc., Montreal, Canada) with a length of 10 cm, 21-gauge, and an active tip length of 5 mm is inserted vertically into the puncture point. The pulse treatment generator is set to the pulsed radiofrequency automatic mode, with a temperature of 42 °C, pulse frequency of 2 Hz, pulse width of 20 ms, and treatment duration of 360s.
Study NCT03567590 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nerve Block treatment
Description: A mixture of 40 mg Triamcinolone + 2 ml of 1% Bupivacaine + 2 ml of 2% mepivacaine + 1:100000 epinephrine is injected for nerve block treatment using a puncture needle.
Study NCT00233324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surfactant
Description: Intubation and administration of surfactant by 1 hour of age.
Study NCT03206918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Zanubrutinib 160 mg (two - 80 mg white opaque capsules) taken by mouth (PO) twice a day (BID)
Study NCT03501992 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Current care
Description: The current care arm consists of the contemporary efforts now in practice to support provider recommendation including a shared, standard immunization schedule, a shared rooming process, a shared well child visit schedule, a shared electronic prompt at point-of-care of vaccines due.
Study NCT03501992 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Reminder-recall
Description: The communication will use expectant (announcement-style or presumptive) language noting the child's HPV vaccination status and stating that the child's provider strongly recommends the child receive the HPV vaccination now. The communication will also describe availability of topical anesthetics (less pain), indicate the availability and convenience of nurse visits for HPV vaccination (less fuss), and describe the immunological and logistical benefits of early vaccination (right now).
Study NCT03501992 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Audit-and-feedback
Description: The intervention includes two components. The first is a missed opportunities audit-and-feedback. The second is a provision of a strong recommendation provider-toolkit, along with a broad education of the practice staff-nurses, medical secretaries, receptionists, and clinical assistants-regarding the nature of the intervention, its goals, and its likely impact on the practice. The broad education will be conducted through supervisory communications only to practice staff in practices allocated to the intervention at the beginning of the step.
Study NCT03501992 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Combined reminder-recall and audit-and-feedback
Description: The combination reminder-and-audit arm consists of a simultaneous application of the intervention tested in the reminder-recall arm and the intervention tested in the audit-and-feedback arm.
Study NCT02845193 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CAD/NAM
Description: computer aided design NAM
Study NCT04142112 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ohana IVF Sperm Preparation Kit (OHB035)
Description: The Ohana IVF Sperm Preparation Kit (OHB035) contains media for processing sperm through a series of timed steps prior to insemination with oocytes.
Study NCT04142112 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard IVF Preparation Kit (OHB037)
Description: The Standard IVF Sperm Preparation Kit (OHB037) contains media for processing sperm per the traditional steps prior to insemination with oocytes.
Study NCT00815360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravitreal injection of ranibizumab
Description: intravitreal injection of 0.5 mg ranibizumab
Study NCT00233324 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Description: Continuous Positive Airway Pressure/Positive End Expiratory Pressure (CPAP/PEEP) begun in the delivery room and continuing in the NICU
Study NCT00815360 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral laser
Description: ultra-widefield fluorescein angiography guided peripheral laser
Study NCT00815360 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravitreal injection of triamcinolone acetonide
Description: intravitreal injection of 4.0 mg triamcinolone acetonide
Study NCT00815360 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: macular laser
Description: macular laser to areas of retinal thickening or leakage
Study NCT02031718 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Counseling